Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare safety and the oxidative stress potential of two
doses of an investigational IV iron, ferric carboxymaltose (FCM), compared to an equal single
dose of IV iron sucrose or IV iron dextran in the treatment of Iron Deficiency Anemia (IDA)
in female subjects.
Phase:
Phase 2
Details
Lead Sponsor:
American Regent, Inc. Luitpold Pharmaceuticals
Treatments:
Dextrans Ferric Compounds Ferric Oxide, Saccharated Iron Iron-Dextran Complex